【 以下文字转载自 Military 讨论区 】 发信人: ts78 (ts), 信区: Military 标 题: Re: FDA grants ‘emergency use’ coronavirus test that can 发信站: BBS 未名空间站 (Sat Mar 21 15:39:40 2020, 美东)
Diagnostics company Cepheid on Saturday said it has received emergency authorization from the U.S. Food and Drug Administration to use its rapid molecular test for point-of-care patients that can detect the virus that causes COVID-19 in 45 minutes.
This is the first coronavirus test that can be conducted entirely at the point-of-care for patients and deliver results in less than an hour. Typically, tests are sent to central reference labs that can take several days to deliver results.
The test, called SAR-CoV-2 Xpert Xpress, was developed by Cepheid, a Sunnyvale, California, company was designed to detect SARS-CoV-2, the virus that is causing COVID-19.
Cepheid uses a testing machine called GeneXpert that can run a full test in 45 minutes. There are currently more than 23,000 automated GeneXpert systems worldwide, with nearly 5,000 of them in the U.S., Cepheid said in a statement.
Cepheid uses a very similar technology for flu tests.
“During this time of increased demand for hospital services, clinicians urgently need an on-demand diagnostic test for real-time management of patients being evaluated for admission to health-care facilities. An accurate test delivered close to the patient can be transformative — and help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on health-care facilities that need to properly allocate their respiratory isolation resources,” Dr. David Persing, MD, Ph.D., chief medical and technology officer at Cepheid said in a statement.
Cepheid President Warren Kocmond added that its automated systems “do not require users to have specialty training” to perform the tests.
【 以下文字转载自 Military 讨论区 】
发信人: ts78 (ts), 信区: Military
标 题: Re: FDA grants ‘emergency use’ coronavirus test that can
发信站: BBS 未名空间站 (Sat Mar 21 15:39:40 2020, 美东)
Diagnostics company Cepheid on Saturday said it has received emergency
authorization from the U.S. Food and Drug Administration to use its rapid
molecular test for point-of-care patients that can detect the virus that
causes COVID-19 in 45 minutes.
This is the first coronavirus test that can be conducted entirely at the
point-of-care for patients and deliver results in less than an hour.
Typically, tests are sent to central reference labs that can take several
days to deliver results.
The test, called SAR-CoV-2 Xpert Xpress, was developed by Cepheid, a
Sunnyvale, California, company was designed to detect SARS-CoV-2, the virus that is causing COVID-19.
Cepheid uses a testing machine called GeneXpert that can run a full test in 45 minutes. There are currently more than 23,000 automated GeneXpert systems worldwide, with nearly 5,000 of them in the U.S., Cepheid said in a
statement.
Cepheid uses a very similar technology for flu tests.
“During this time of increased demand for hospital services, clinicians
urgently need an on-demand diagnostic test for real-time management of
patients being evaluated for admission to health-care facilities. An
accurate test delivered close to the patient can be transformative — and
help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on health-care facilities that need to properly allocate their
respiratory isolation resources,” Dr. David Persing, MD, Ph.D., chief
medical and technology officer at Cepheid said in a statement.
Cepheid President Warren Kocmond added that its automated systems “do not
require users to have specialty training” to perform the tests.
雨中 又 牛逼了
有在这上班的吗